Projects

First-in-human CAN-3110 study shows longer median survival and good safety in recurrent high-grade glioma

https://www.businesswire.com/news/home/20210604005138/en/Candel-Therapeutics-Announces-Data-from-Phase-1-Trial-of-CAN-3110-in-Recurrent-High-Grade-Glioma-at-the-2021-American-Society-of-Clinical-Oncology-ASCO-Annual-Meeting

Next

What GSK’s Immunology Chief Did Next

Paul-Peter Tak
Contact Me

Paul Peter Tak

contact@paulpetertak.com

Paul Peter Tak

© Paul Peter Tak.
All rights reserved. 

Social

Scholar